Publications

Found 32 results
Author Title Type [ Year(Asc)]
Filters: Author is Kaplitt, Michael G  [Clear All Filters]
2017
Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A et al..  2017.  Long-term follow-up of a randomized AAV2- gene therapy trial for Parkinson's disease.. JCI Insight. 2(7):e90133.
2016
Marongiu R, Arango-Lievano M, Francardo V, Morgenstern P, Zhang X, M Cenci A, Svenningsson P, Greengard P, Kaplitt MG.  2016.  Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice.. Proc Natl Acad Sci U S A. 113(5):1423-8.
Virk MS, Sagi Y, Medrihan L, Leung J, Kaplitt MG, Greengard P.  2016.  Opposing roles for serotonin in cholinergic neurons of the ventral and dorsal striatum.. Proc Natl Acad Sci U S A. 113(3):734-9.
Schintu N, Zhang X, Alvarsson A, Marongiu R, Kaplitt MG, Greengard P, Svenningsson P.  2016.  p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism.. Proc Natl Acad Sci U S A. 113(5):1429-34.
2013
Gelfand Y, Kaplitt MG.  2013.  Gene therapy for psychiatric disorders.. World Neurosurg. 80(3-4):S32.e11-8.
2010
Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Lievano M, Ghose S, Vernov M, Stavarache M, Musatov S, Flajolet M et al..  2010.  Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med. 2(54):54ra76.
2007
Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D et al..  2007.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 369(9579):2097-105.